The Limited Times

Now you can see non-English news...

Pfizer posts record second-quarter revenue

2022-07-28T13:50:59.928Z


Boosted by the sales of its vaccine and its anti-Covid pill, the laboratory saw its net profit soar over the period.


Sales of Pfizer's anti-Covid vaccine and pill boosted its results in the second quarter, with the American pharmaceutical group still planning to sell $54 billion of them for the year as a whole.

From April to June, the laboratory's turnover jumped 47% to reach 27.74 billion dollars, a record.

Read also“

Covid: the race against time for the CEO of Pfizer

SEE ALSO

- Pfizer is committed to selling vaccines and drugs for non-profit purposes to the poorest countries

Its net profit meanwhile soared 78% to $9.9 billion.

Sales of the vaccine against Covid-19 Comirnaty, developed in collaboration with the German group BioNTech, reached 8.8 billion dollars (+20% compared to the same period in 2021), with an increase in sales in the countries emerging markets and deliveries to certain developed countries.

Deliveries, on the other hand, slowed in the United States and Canada.

Sales of the anti-Covid pill Paxlovid, launched at the end of 2021 and recently used by US President Joe Biden, for their part reached 8.1 billion dollars.

Without these two products, and without currency effects, Pfizer's sales would have increased by only 1%.

Sales of its smoking cessation treatment Champix have notably been reduced to almost nothing, the group having suspended its distribution due to the excessive presence of a potentially carcinogenic component.

The laboratory maintained its forecasts for the full year, despite a greater than initially expected impact of exchange rate effects on its revenues: the rise in the dollar lowers the value of profits earned abroad when they are converted into US currency.

SEE ALSO

- EDF suffers an exceptional loss of 5.3 billion euros in the first half

Source: lefigaro

All business articles on 2022-07-28

You may like

Trends 24h

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.